NCT06370000 2026-03-02
REMAIN1
Virginia Commonwealth University
Phase 4 Recruiting
Clinical Trials
4 trialsNCT07044687 2026-01-12
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
AbbVie
Phase 4 Recruiting
NCT05144243 2025-08-12
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
AbbVie
Phase 4 Active not recruiting
NCT03873311 2022-03-15
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
Shenzhen Second People's Hospital
Phase 4 Unknown